Skip to main content
Premium Trial:

Request an Annual Quote

Frank Witney

RareCyte has appointed Frank Witney to its board of directors. Most recently, Witney served as president and CEO of Affymetrix, recently acquired by Thermo Fisher Scientific. He has previously served as president and CEO of Dionex and as president and CEO of Panomics, a subsidiary of Affymetrix. Prior to that, Witney served as president of PerkinElmer's Drug Discovery Tools division before it was acquired by Packard Bioscience in 2001. He served as president and chief operating officer at Packard Biosciences and he has also held leadership positions at Bio-Rad Laboratories.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.